No abstract

BackgroundFCGR1A encodes a protein that plays an important role in the immune response. The prognostic impact and immune infiltration of FCGR1A in heterogeneous cancers remain unclear.MethodsDifferential expression of FCGR1A between tumor and normal tissues and the discrepancies in overall survival (OS) among diverse cancer types were performed by Gene Expression Profiling Interactive Analysis. The correlation between FCGR1A and immune cells or gene marker sets of immune infiltrates was analyzed via Tumor Immune Estimation Resource (TIMER). Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and protein-to-protein interaction (PPI) network were used to explore the function and related genes of FCGR1A. The relationships among these genes were further analyzed by TIMER.ResultsFCGR1A is highly expressed in various cancer types. FCGR1A was significantly correlated with the OS of cervical and endocervical cancer (CESC), cholangiocarcinoma (CHOL), kidney renal clear cell carcinoma (KIRC), and skin cutaneous melanoma (SKCM) (P < 0.05). High expression of FCGR1A meant a better prognosis besides KIRC. FCGR1A showed significant differences at different stages of KIRC and SKCM (P < 0.05). Furthermore, FCGR1A was notably associated with infiltrating levels of CD4+ T cells, CD8+ T cells, B cells, macrophages, neutrophils, and dendritic cells in the four cancers (P < 0.05). FCGR1A also showed close relevance with different immune gene markers. The copy number variation of FCGR1A significantly influenced the abundance of immune infiltration in KIRC and SKCM. GO, KEGG analysis, and PPI network analysis revealed that FCGR1A is involved in many pathophysiological processes and was most related to FCGR3A. And this gene indicated highly significant positive correlations with FCGR1A in four cancers.ConclusionFCGR1A may be a potential prognostic biomarker and related to immune infiltration levels in diverse cancers, especially in CESC, CHOL, KIRC, and SKCM. Besides, FCGR1A may be involved in the activation, regulation, or induction of immune cells and diverse physiological and pathological processes.

No abstract

Background: FCGR1A encodes a protein that plays an important role in the immune response. The prognosis and tumor immune infiltration of FCGR1A in heterogeneous tumors remains unclear.Methods: Differential expression analysis of FCGR1A between tumor and normal tissues and the difference in overall survival (OS) among different cancer types were performed by Gene Expression Profiling Interactive Analysis (GEPIA). The correlation between FCGR1A and cancer immune infiltration or immue gene markers was completed through Tumor Immune Estimation Resource (TIMER) site. Results: FCGR1A exhibited high expression in various cancer types. FCGR1A was significantly correlated with the overall survival (OS) of cervical and endocervical cancer (CESC), cholangiocarcinoma (CHOL), kidney renal clear cell carcinoma (KIRC) and skin cutaneous melanoma (SKCM) (P<.05). High expression of FCGR1A meant a better prognosis except for KIRC. FCGR1A showed significant differences at different stages of KIRC and SKCM (P<.05). Furthermore, FCGR1A was notably associated with immune infiltrating levels of CD4+ T cell, CD8+ T cell, B cell, macrophage, neutrophil, and dendritic cell in the four cancers (P<.05). FCGR1A also showed close relevance with different immune gene markers. The copy number variation (CNV) of FCGR1A significantly influenced the abundance of immune infiltration in KIRC and SKCM. Conclusion: FCGR1A may be a potential prognostic biomarker and related to immune infiltration levels in diverse cancers, especially in CESC, CHOL, KIRC, and SKCM. Besides, FCGR1A may be involved in the activation, regulation or induction of immune cells.

Background and Objectives: Chronic obstructive pulmonary disease (COPD) is a common, frequently-occurring disease and poses a major health concern. Unfortunately, there is current no effective treatment for COPD, particularly emphysema. Recently, experimental treatment of COPD using mesenchymal stem cells (MSCs) mainly focused on bone marrow-derived MSCs (BM-MSCs). Human umbilical cord-derived MSCs (hUC-MSCs) have more advantages compared to BM-MSCs. However, studies on the role of hUC-MSCs in management of COPD are limited. This study sought to explore the role of hUC-MSCs and its action mechanisms in a rat model of VEGF receptor blocker SU5416-injured emphysema. Methods and Results: hUC-MSCs were characterized by immunophenotype and differentiation analysis. Rats were divided into four groups: Control, Control＋MSC, SU5416 and SU5416＋MSC. Rats in model group were administered with SU5416 for three weeks. At the end of the second week after SU5416 administration, model group were infused with 3×10 6 hUC-MSCs through tail vein. After 14 days from hUC-MSCs transplantation, rats were euthanized and data were analyzed. HE staining and mean linear intercepts showed that SU5416-treated rats exhibited typical emphysema while emphysematous changes in model rats after hUC-MSCs transplantation disappeared completely and were restored to normal phenotype. Furthermore, hUC-MSCs inhibited apoptosis as shown by TUNEL and Western blotting. ELISA and Western blotting showed hUC-MSCs rescued VEGF-VEGFR2-AKT pathway in emphysematous lungs. Conclusions: The findings show that hUC-MSCs effectively repair the emphysema injury. This study provides the first evidence that hUC-MSCs inhibit apoptosis via rescuing VEGF-VEGFR2-AKT pathway in a rat model of emphysema.

Anaplastic lymphoma kinase (ALK) rearrangements account for approximately 5–6% of non–small-cell lung cancer (NSCLC) patients. In this study, a case of lung adenocarcinoma harboring a novel MRPS9-ALK fusion is reported. The patient responded well to the first and second generation of ALK-tyrosine kinase inhibitors (ALK-TKIs) (crizotinib then alectinib), as her imaging findings and clinical symptoms significantly improved. At last follow-up, over 21 months of overall survival (OS) has been achieved since ALK-TKI treatment. The progression-free survival (PFS) is already ten months since alectinib. The adverse effects were manageable. The case presented here provides first clinical evidence of the efficacy of ALK-TKIs in NSCLC patients with MRPS9-ALK fusion.

No abstract

Background: Marital status has been proved as an independent prognostic factor in many cancer types. However, no detailed investigation of marital status on squamous cell carcinoma (SCC) has been evaluated. The aim of this essay is to explore the relationship between marital status and SCC in 7 tumor sites. Methods: All patients diagnosed with SCC were collected from the SEER database (1975-2016). We analyzed the survival of all included SCC patients in four marital status. We utilized propensity-score matching analysis to balance baseline characteristics between married and unmarried SCC patients in 7 tumor sites. The influence of marital status on overall survival (OS) in each site was performed by Cox regression analysis.Results: A total of 180009 SCC patients were involved in this study. After propensity-score matching, patients in the married group were 1:1 matched with patients in the unmarried group for each sites. Married group exhibited higher 5- year OS rate than unmarried group (27.3% vs 19.8%). More precisely, being divorced and widowed were observed to be related to have worse survival than single patients in most sites. Furthermore, patients with clinical stage IV were more common in the unmarried group which having a lower proportion of receiving treatment. Conclusions: This study indicated that marital status was a significant factor for OS of SCC in 7 tumor sites. Married patients always behaved more favorable than unmarried including single, divorced, and widowed patients.